^
BIOMARKER:

KRAS G12V

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS G12V
CRC
panitumumab
Sensitive: B - Late Trials
KRAS G12V
CRC
cetuximab
Resistant: B - Late Trials
KRAS G12V
NSCLC
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
KRAS G12V
NSCLC
selumetinib
Sensitive: C3 – Early Trials
KRAS G12V
Spindle Cell Sarcoma
BAL3833
Sensitive: C3 – Early Trials
KRAS G12V
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
KRAS G12V
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
KRAS G12V
HCC
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
KRAS G12V
NSCLC
erlotinib
Resistant: C3 – Early Trials
KRAS G12V
NSCLC
VS-6766
Sensitive: C3 – Early Trials
KRAS G12V
CRC
RGX-202
Sensitive: C3 – Early Trials
KRAS G12V
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
KRAS G12V
CRC
bevacizumab + PCM-075
Sensitive: C3 – Early Trials
KRAS G12V
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
KRAS G12V
CRC
FOLFOX
Resistant: C3 – Early Trials
KRAS G12V
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
KRAS G12V
LUAD
osimertinib
Resistant: C4 – Case Studies
KRAS G12V
CRC
AZ 628
Resistant: D – Preclinical
KRAS G12V
Colon Cancer
CDK9 inhibitor
Sensitive: D – Preclinical
KRAS G12V
CRC
selumetinib + AZ 628
Sensitive: D – Preclinical
KRAS G12V
CRC
selumetinib
Resistant: D – Preclinical
KRAS G12V
NSCLC
palbociclib
Sensitive: D – Preclinical
KRAS G12V
NSCLC
JQ-1
Sensitive: D – Preclinical
KRAS G12V
CRC
sunitinib
Resistant: D – Preclinical
KRAS G12V
Ovarian Cancer
trametinib
Sensitive: D – Preclinical
KRAS G12V
CRC
P1446A-05
Sensitive: D – Preclinical